BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21645449)

  • 1. [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
    Qin X; Liu B; Li Y; You J; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):478-83. PubMed ID: 21645449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism].
    Jia YL; Zhao Y; Zhen SM; Cheng ZS; Zheng BY; Liu YP; Liu LH
    Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):779-786. PubMed ID: 37805442
    [No Abstract]   [Full Text] [Related]  

  • 3. [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
    Wang Q; Li M; Hu C
    Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):193-8. PubMed ID: 25936882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
    Yang B; Yang ZG; Gao B; Shao GG; Li GH
    Int J Clin Exp Pathol; 2015; 8(10):12961-6. PubMed ID: 26722491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
    Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
    Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
    Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
    Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
    Ju LX; Zhou CC; Tang L; Zhao YM; Yang XJ; Su B; Meng SY; Li W; Yan LH; Ding YM
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 May; 33(5):354-8. PubMed ID: 20646614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.
    Ge X; Zheng L; Huang M; Wang Y; Bi F
    Mol Med Rep; 2015 Jan; 11(1):333-40. PubMed ID: 25339453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells.
    Zhu W; Wang JP; Meng QZ; Zhu F; Hao XF
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4306-4313. PubMed ID: 32373967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
    Deng QF; Su B; Zhao YM; Zhou CC
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):813-6. PubMed ID: 19173824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro.].
    Wei W; Fan Y; Liu H; Wu Z; Wan H; Yan Z; Xu K; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2009 Jan; 12(1):28-32. PubMed ID: 20712953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance.
    Lin CC; Chen JT; Lin MW; Chan CH; Wen YF; Wu SB; Chung TW; Lyu KW; Chou HC; Chan HL
    Toxicol Appl Pharmacol; 2015 Nov; 288(3):359-73. PubMed ID: 26298006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
    Ju L; Zhou C; Li W; Yan L
    J Cell Biochem; 2010 Dec; 111(6):1565-74. PubMed ID: 21053345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
    Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
    Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
    Jiang J; Feng X; Zhou W; Wu Y; Yang Y
    Oncotarget; 2016 Nov; 7(45):73188-73199. PubMed ID: 27690301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
    Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
    J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
    Lee Y; Choi YR; Kim KY; Shin DH
    Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.